Summary
ADMA Biologics Inc (ADMA Biologics) is a drug development company that offers specialty plasma-based biologics. The company develops RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin, derived from human plasma containing naturally occurring polyclonal antibodies. ADMA Biologics’ target treatment areas include bacterial infections, respiratory syncytial virus and primary immune deficiency diseases. The company also operates bio centers, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of its products. ADMA Biologics is headquartered in Ramsey, New Jersey, the US.
ADMA Biologics Inc (ADMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
ADMA Biologics Acquires Certain Assets from Biotest Pharma 11
Venture Financing 12
ADMA Biologics to Secure USD21 Million from Oxford Finance 12
Adma Biologics Secures USD5 Million from Hercules 13
ADMA Biologics Secures Venture Funding from Biomark Capital 14
ADMA Plasma Biologics Raises US$17.6 Million In Venture Financing 15
Licensing Agreements 15
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 15
Adma Biologics Enters Into Licensing Agreement With Biotest For IGIV 16
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 17
Equity Offering 18
ADMA Biologics Plans to Raise Funds through Secondary Offering of Shares 18
ADMA Biologics Raises USD14 Million in Public Offering of Shares 19
ADMA Biologics Raises USD11.2 Million in Public Offering of Shares 21
ADMA Biologics Completes IPO For US$28.5 Million 22
ADMA Biologics Completes Private Placement Of Shares For US$17.6 Million 23
Acquisition 25
R&R Acquisition Acquires ADMA Biologics In Reverse Acquisition 25
ADMA Biologics Inc - Key Competitors 26
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
May 12, 2017: ADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results 29
Feb 24, 2017: ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones 30
Nov 10, 2016: ADMA Biologics Reports Third Quarter 2016 Results 31
Aug 12, 2016: ADMA Biologics Reports Second Quarter 2016 Results 32
May 13, 2016: ADMA Biologics Reports First Quarter 2016 Results 33
Mar 23, 2016: ADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones 34
Other Significant Developments 36
Jun 27, 2017: ADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders 36
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ADMA Biologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ADMA Biologics Acquires Certain Assets from Biotest Pharma 11
ADMA Biologics to Secure USD21 Million from Oxford Finance 12
Adma Biologics Secures USD5 Million from Hercules 13
ADMA Biologics Secures Venture Funding from Biomark Capital 14
ADMA Plasma Biologics Raises US$17.6 Million In Venture Financing 15
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 15
Adma Biologics Enters Into Licensing Agreement With Biotest For IGIV 16
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 17
ADMA Biologics Plans to Raise Funds through Secondary Offering of Shares 18
ADMA Biologics Raises USD14 Million in Public Offering of Shares 19
ADMA Biologics Raises USD11.2 Million in Public Offering of Shares 21
ADMA Biologics Completes IPO For US$28.5 Million 22
ADMA Biologics Completes Private Placement Of Shares For US$17.6 Million 23
R&R Acquisition Acquires ADMA Biologics In Reverse Acquisition 25
ADMA Biologics Inc, Key Competitors 26
ADMA Biologics Inc, Key Employees 27
ADMA Biologics Inc, Subsidiaries 28
List of Figures
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
